-
MyChart
Log in to our secure, personalized website to manage your care (formerly myMDAnderson).
-
Request an Appointment
Request an Appointment
If you are ready to make an appointment, select a button on the right. If you have questions about MD Anderson’s appointment process, our information page may be the best place to start.
Appointment Information - Donate Today
Study #2016-0515
PHASE 1 CELL DOSE ESCALATION STUDY TO ASSESS THE SAFETY AND TOLERABILITY OF GENETICALLY ENGINEERED MAGE-A10 C796T IN HLA-A2+ SUBJECTS WITH MAGE-A10 POSITIVE UROTHELIAL, MELANOMA OR HEAD AND NECK TUMORS
Study Status
Open
Treatment Agent
Cyclophosphamide,Fludarabine,MAGE-A10c796T,MESNA,Neupogen
Principal Investigator
David S. Hong
Description
T cells are a type of white blood cell that work as a part of your immune system. In this study, your own T cells will be collected and genetically changed to make the MAGE-A10 study drug. The study drug is designed to use your genetically changed T cells to specifically target and attack cancer cells. The goal of this clinical research study is to find the highest tolerable dose of the study drug that can be safely given to cancer patients. Researchers also want to learn about possible side effects of the study drug and if the study drug can help to control the disease.
General Information
Disease Group: Malignant neoplasms of ill-defined secondary and unspecified sites,Malignant neoplasms of urinary tract,Melanoma and other malignant neoplasms of skin
Treatment Agent: Cyclophosphamide,Fludarabine,MAGE-A10c796T,MESNA,Neupogen
Treatment Location: Both at MDACC & and Other Sites
Sponsor: STRATEGIC ALLIANCE: Adaptimmune, LLC
Study Status
IRB Review and Approval Date: 12/09/2016
Recruitment Status: Open
Projected Accrual: 22
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Malignant neoplasms of ill-defined secondary and unspecified sites,Malignant neoplasms of urinary tract,Melanoma and other malignant neoplasms of skin
Study phase:
Phase I
Physician name:
David S. Hong
Department:
Investigational Cancer Therapeutics
For general questions about clinical trials:
1-877-632-6789